A Pilot Study of Microbiome in Patients With Autism Spectrum Disorder and Their Unaffected Siblings

A Pilot Study of Microbiome in Patients With Autism Spectrum Disorder and Their Unaffected

The primary aims are to identify important gut microbiota signatures for youth with ASD, to identify dysbiosis features for different levels of ASD features and clinical courses, to search the possibility to intervene the disease course if we can tease out the dysbiosis responsible for the flare-up and improvement of the symptoms of the disease. The secondary aims are to identify the clinical and neuropsychological measures that are associated with direct and indirect regulation or interactions from gut-brain axis signaling, and based our preliminary results on reducing the measures for future large-scale microbiome study in ASD.

Study Overview

• Status: Completed
• Conditions: Autism Spectrum Disorder
• Intervention / Treatment: Other: ASD diagnosis; Other: Psychiatric diagnosis

Detailed Description

Background: Despite increased public awareness of autism spectrum d isorder (ASD) and extensive research on this neurodevelopmental disorder in the past decades, the underlying mechanisms of ASD remain unclear, and ASD is still recognized as having the highest disease and care burden among child psychiatric disorders regarding its long-term impairment across the lifespan. Hence, identifying the biomarkers for early detection and effective biological treatments for ASD is among the most challenging tasks all over the world. The concerns about physical comorbidities such as immune dysregulation, allergy, and gastrointestinal issues, etc. emerged in the recent decade. Hence, the new perspective of searching for the underlying mechanism for ASD also targets the associations between microbiota and ASD. However, despite many microbiome studies in ASD, they provided limited knowledge about the specific link that particular imbalance gut bacteria could affect the behavioral deficits in ASD because lack of consideration of the clinical and genetic heterogeneity of ASD. With only a few studies examining the well-defined ASD-related impairments, the GI system dysfunction, and the microbiomes, the associations among ASD-related symptoms, GI symptoms, and microbiota remain indistinct. Therefore, the investigators propose this pilot study to fill the gap between the potential role of microbiome as a biomarker for ASD to facilitate developing the treatment for ASD.

Method and material: The case-sibling control study design will be used to investigate microbiome in 60 probands with ASD, aged 7-25 yrs old, and 30 unaffected siblings either from the PI Gau's ASD cohort or the Department of Psychiatry, National Taiwan University Hospital. The parents of all the subjects will receive the Autism Diagnostic Interview-Revised (ADI-R) interviews and report on the questionnaires regarding autistic symptoms, emotional/behavioral problems, social functions, G-I symptoms, and life quality. The ASD and sibling subjects will receive the Autism Diagnostic Observation Scale and neuropsychological tasks. The experiment of microbiome will be conducted by the core lab of microbiome (co-PI Ni) at the college of medicine, National Taiwan University. The data analyses will combine microbiomics and the extensive behaviors/cognitive function variables to establish an objective potential pipeline.

Anticipated outcome: With the accomplishment of this project, the investigators will establish the comprehensive yet fewer bios for the ASD risk bio-factors in Asia, and provide the potential clinical interview and assessments related to GI symptoms regulated by microbiota. The potential biomarkers may be further used to developing the treatment for ASD.

Significance: Several features of this project constitute its significance: a wealth of measures of ASD phenotypes (valid phenotype), ASD as a catastrophic disease (importance), the first ASD study with unaffected sibling design for microbiomics studies in ASD (originality), and new approaches and technologies (novelty) for searching microbiomics in ASD.

• Study Type: Observational
• Enrollment (Actual): 150

Contacts and Locations

Study Locations

• Taiwan
  • Taipei, Taiwan
    • National Taiwan Univeristy Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 7 years to 25 years (ADULT, CHILD)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

The cohort was established at the Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007.

Description

Inclusion Criteria:

• a clinical diagnosis of ASD defined by the DSM-IV confirmed by ADI-R or ADOS and also clinical reappraisal based on the newly release DSM-5 criteria for ASD
• ages range from 7 to 25 at the time now
• at least one biological parent
• parents that are both Han Chinese in Taiwan

Exclusion Criteria:

• intellectual disability
• epilepsy
• ADHD
• autoimmune diseases

Study Plan

How is the study designed?

Number of groups / cohorts

3

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
ASD group; 80 youths with the clinical diagnosis of ASD according to the DSM-5 diagnostic criteria	Other: ASD diagnosis; Autism Diagnostic Interview-revised (ADI-R) and Autism Diagnostic Observation Scale (ADOS); Other: Psychiatric diagnosis; Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
Sibling group; 30 unaffected siblings of ASD youths	Other: Psychiatric diagnosis; Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5
TD group; 40 healthy typical developing(TD) control from cohort established at Department of Psychiatry, National Taiwan University Hospital (NTUH) starting from 2007	Other: Psychiatric diagnosis; Kiddie Schedule for Affective Disorders & Schizophrenia (K-SADS) for DSM-5

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Autism Diagnostic Interview-Revised (ADI-R)	Including reciprocal social interaction, communication, and repetitive behaviors and stereotyped patterns, for children with a mental age from about 18 months into adulthood. The coding of some items is converted to numeric scores "0" if no evidence of abnormality exists, "1" if some evidence of abnormality exists, and "2" if evidence of marked abnormality. Higher scores mean more severe clinical deficits.	1 hour
Autism Diagnostic Observation Scale (ADOS)	Including communication, social interaction, creativity, stereotyped behaviors and restricted interests. The coding of some items is converted to numeric scores "0" if no evidence of abnormality exists, "1" if some evidence of abnormality exists, and "2" if evidence of marked abnormality. Higher scores mean more severe clinical deficits.	1 hour

Collaborators and Investigators

• Sponsor: National Taiwan University Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): January 1, 2019
• Primary Completion (ACTUAL): December 31, 2020
• Study Completion (ACTUAL): December 31, 2020

Study Registration Dates

• First Submitted: September 1, 2021
• First Submitted That Met QC Criteria: September 1, 2021
• First Posted (ACTUAL): September 9, 2021

Study Record Updates

• Last Update Posted (ACTUAL): September 16, 2021
• Last Update Submitted That Met QC Criteria: September 8, 2021
• Last Verified: January 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Neurodevelopmental Disorders; Autistic Disorder; Autism Spectrum Disorder; Child Development Disorders, Pervasive
• Other Study ID Numbers: 201810048RIND

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No